20VC: Brex Acquired for $5.15BN | a16z Companies are 2/3 AI Revenues | Anthropic Inference Costs Skyrocket | OpenEvidence Raises at $12BN Valuation | The IPO Market: EquipmentShare, Wealthfront and Ethos Insurance

What It Covers

This episode analyzes major tech deals including Brex's $5.15 billion acquisition by Capital One, Open Evidence's $12 billion valuation, and Anthropic's rising inference costs. The hosts debate whether AI companies can achieve profitability, examine the IPO market's reopening with Equipment Share and Ethos, and discuss implications for SaaS companies competing against well-funded AI-first competitors.

Key Questions Answered

• •Brex Exit Analysis: Capital One acquired Brex for $5.15 billion (50% cash, 50% stock), down from its 2021 peak valuation of $12 billion. Despite appearing disappointing versus the 2021 raise, this represents a heroic outcome for founders building to $5 billion before age 30. The deal validates that financial services companies ultimately trade at financial services multiples adjusted for growth, with Brex at approximately 7x revenue on $700 million run rate.
• •Hubristic Financing Risk: Companies raising at peak valuations face a one-day emotional tax when exiting lower, but the alternative of not raising when capital is available would be worse. The strategy works when founders believe they can grow into valuations within two years. Databricks' approach of never raising more than two years ahead of confident valuation targets provides a framework for managing this risk while maintaining competitive positioning against well-funded rivals.
• •Ramp Competitive Position: Ramp's $32 billion valuation faces new scrutiny after Brex sold at 7x revenue. If Ramp maintains $1 billion run rate and faster growth, a 10x multiple at IPO seems reasonable, but Capital One's acquisition of both Discover and Brex creates a formidable competitor with structural cost advantages through closed-loop interchange networks. Ramp must now compete against an A-team with better economics while justifying its 30x+ revenue multiple.
• •Inference Cost Reality: Anthropic's inference costs came in 23% higher than expected, yet gross margins improved from negative 94% last year to positive 40% this year. For B2B companies, inference represents an unavoidable competitive cost that will increase, not decrease, as companies burn more tokens to deliver better agents. Mid-market SaaS companies at $50-200 million ARR face existential challenges funding competitive AI products against rivals with unlimited capital.
• •Open Evidence Valuation: The company raised at $12 billion on approximately $150 million revenue (80x multiple), representing a 12x step-up from its $1 billion valuation earlier in 2025. While the company dominates physician decision support and has clear product-market fit, the direct-to-doctor pharmaceutical advertising market is only $2-3 billion annually. Reaching justifiable public market valuations requires either capturing pharma rep budgets or expanding into adjacent physician services.
• •IPO Market Bifurcation: Equipment Share's successful IPO at $8 billion market cap (growing 47% at $4 billion revenue, profitable) contrasts sharply with Wealthfront's struggling $1.3 billion debut (down 36% from IPO). The market clearly delineates at $3 billion market cap—above this threshold, IPOs proceed smoothly with liquidity; below it, companies face years of illiquidity and talent retention challenges regardless of product quality or mission.